+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Unresectable Hepatocellular Carcinoma Market by Therapy Type, Mechanism Of Action, Line Of Therapy, Formulation, Distribution Channel, End User - Global Forecast to 2030- Product Image
Unresectable Hepatocellular Carcinoma Market by Therapy Type, Mechanism Of Action, Line Of Therapy, Formulation, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Unresectable Hepatocellular Carcinoma Market by Therapy Type, Mechanism Of Action, Line Of Therapy, Formulation, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715740
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Unresectable Hepatocellular Carcinoma Market is rapidly evolving, driven by advances in immunotherapy, targeted agents, and changes within the global regulatory landscape. Stakeholders across healthcare, pharmaceuticals, and policy must navigate complex dynamics to effectively position themselves in this growing sector.

Market Snapshot: Unresectable Hepatocellular Carcinoma Market

The Unresectable Hepatocellular Carcinoma Market grew from USD 1.90 billion in 2024 to USD 2.16 billion in 2025. It is expected to continue growing at a CAGR of 13.47%, reaching USD 4.05 billion by 2030. This trajectory reflects the market's response to innovations in therapy, increased awareness, and the urgency for tailored solutions in liver cancer care. The primary keyword, unresectable hepatocellular carcinoma market, underscores a strategic focus for industry leaders aiming to capture demand and enhance patient outcomes in this oncology segment.

Scope & Segmentation

This report delivers a comprehensive forecast and analysis across the following areas:

  • Therapy Types: Combination therapy, locoregional therapy, supportive care, systemic therapy
  • Mechanisms of Action: Immune checkpoint inhibitors (CTLA-4 inhibitors, PD-1 inhibitors, PD-L1 inhibitors), mTOR inhibitors, tyrosine kinase inhibitors (multi kinase inhibitors, selective kinase inhibitors)
  • Lines of Therapy: First-line, second-line, third-line options
  • Formulations: Injectable, oral
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies
  • End Users: Home care settings, hospitals, specialty oncology clinics
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East, and Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, and others), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Players: F. Hoffmann-La Roche Ltd, Genentech, Inc., Eisai Co., Ltd., Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Exelixis, Inc., Eli Lilly and Company

Segmenting the market provides expertise to guide product development, partnership strategies, and competitive intelligence tailored for global and local contexts.

Key Takeaways for Decision-Makers

  • Immunotherapy combinations and targeted therapies are steadily shaping the standard of care, requiring organizations to invest in adaptive, biomarker-driven clinical programs.
  • Locoregional interventions and supportive care remain integral, offering control for select patient profiles and maintaining quality of life amidst extended treatment pathways.
  • Market entry barriers differ significantly by region; robust reimbursement frameworks and centralized approvals favor adoption in developed markets while infrastructure limitations shape deployment in emerging geographies.
  • Formulation and distribution preferences are segmenting end-user environments, resulting in diverse supply chain solutions and the need for digital health integration.
  • Strategic collaborations and joint ventures, especially between established pharma and innovative biotech firms, are accelerating the transition from early-stage assets to later-stage trials and market launches.
  • Competitive differentiation increasingly lies in tailored patient support, real-time outcomes tracking, and value communication to institutional buyers and payers.

Tariff Impact on Supply and Pricing

The introduction of new tariffs in 2025 is reshaping supply chains and pricing across pharmaceutical imports to the United States. Manufacturers are adapting by sourcing raw materials from alternative markets, renegotiating contracts, and localizing production where feasible. Some institutions have experienced temporary shortages due to customs clearance delays, prompting a shift toward supplier diversification and increased onshore inventories. Direct engagement with policymakers aims to secure regulatory relief for essential oncology products, while process innovations and scale-up efforts seek to stabilize cost bases.

Methodology & Data Sources

This report synthesizes data from peer-reviewed journals, regulatory filings, industry white papers, and proprietary patent libraries. Insights from key opinion leaders and structured industry interviews provide clinical relevance and operational perspectives. All data undergoes multi-source validation, guided by a dedicated advisory panel to ensure transparency and analytical rigor.

Why This Report Matters

  • Supports confident market entry, portfolio expansion, and investment planning by delivering actionable, segment-specific intelligence.
  • Enables executives to benchmark strategies against global and regional leaders, uncovering opportunities in innovation and operational agility.
  • Helps mitigate risks by clarifying tariff impacts, policy shifts, and best practices in patient engagement and market access.

Conclusion

The unresectable hepatocellular carcinoma market is transitioning through substantial clinical and operational change. Informed, strategic engagement with evolving therapies, regional dynamics, and regulatory developments will drive enduring value for all stakeholders investing in this domain.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Unresectable Hepatocellular Carcinoma Market, by Therapy Type
8.1. Introduction
8.2. Combination Therapy
8.3. Locoregional Therapy
8.4. Supportive Care
8.5. Systemic Therapy
9. Unresectable Hepatocellular Carcinoma Market, by Mechanism Of Action
9.1. Introduction
9.2. Immune Checkpoint Inhibitors
9.2.1. Ctla-4 Inhibitors
9.2.2. Pd-1 Inhibitors
9.2.3. Pd-L1 Inhibitors
9.3. Mtor Inhibitors
9.4. Tyrosine Kinase Inhibitors
9.4.1. Multi Kinase Inhibitors
9.4.2. Selective Kinase Inhibitors
10. Unresectable Hepatocellular Carcinoma Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line
11. Unresectable Hepatocellular Carcinoma Market, by Formulation
11.1. Introduction
11.2. Injectable
11.3. Oral
12. Unresectable Hepatocellular Carcinoma Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Unresectable Hepatocellular Carcinoma Market, by End User
13.1. Introduction
13.2. Home Care Settings
13.3. Hospitals
13.4. Specialty Clinics
14. Americas Unresectable Hepatocellular Carcinoma Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Unresectable Hepatocellular Carcinoma Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Unresectable Hepatocellular Carcinoma Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. F. Hoffmann-La Roche Ltd
17.3.2. Genentech, Inc.
17.3.3. Eisai Co., Ltd.
17.3.4. Bayer AG
17.3.5. Merck & Co., Inc.
17.3.6. Bristol-Myers Squibb Company
17.3.7. Exelixis, Inc.
17.3.8. Eli Lilly and Company
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET MULTI-CURRENCY
FIGURE 2. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET MULTI-LANGUAGE
FIGURE 3. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MULTI KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SELECTIVE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 55. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 56. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 57. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 58. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 59. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 60. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 61. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 64. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 65. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 66. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 68. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 69. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 105. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 106. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 107. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 108. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 109. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 110. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 113. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 114. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 115. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 116. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 117. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 118. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 129. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 130. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 131. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 132. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 133. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 134. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 137. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 138. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 139. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 140. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 141. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 142. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 169. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 170. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 171. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 172. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 173. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 174. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 185. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 186. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 187. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 188. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 189. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 190. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 193. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 194. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 195. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 197. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 198. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 217. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 218. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 219. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 220. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 221. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 222. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 225. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 226. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 227. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 228. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 229. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 230. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 241. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 242. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 243. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 244. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 245. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 246. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 249. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 250. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 251. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 252. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 253. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 254. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 273. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 274. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 275. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 276. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 277. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 278. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 279. CHINA UNRESECTABLE HEPATOCE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Unresectable Hepatocellular Carcinoma market report include:
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Eisai Co., Ltd.
  • Bayer AG
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Exelixis, Inc.
  • Eli Lilly and Company

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.16 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.05 Billion
Compound Annual Growth Rate13.4%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Unresectable Hepatocellular Carcinoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Unresectable Hepatocellular Carcinoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 129 Pages
  • Global
From
Unresectable Hepatocellular Carcinoma Market Report 2025 - Product Image

Unresectable Hepatocellular Carcinoma Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Metastatic Hepatocellular Carcinoma- Pipeline Insight, 2025 - Product Image

Metastatic Hepatocellular Carcinoma- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Hepatocellular Carcinoma Drugs - Global Strategic Business Report - Product Image

Hepatocellular Carcinoma Drugs - Global Strategic Business Report

  • Report
  • 198 Pages
  • Global
From
Transarterial Chemoembolization - Global Strategic Business Report - Product Image

Transarterial Chemoembolization - Global Strategic Business Report

  • Report
  • 375 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.